Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
IONS - Ionis Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$93.36
DETAILS
HIGH:
$115.00
LOW:
$69.00
MEDIAN:
$90.00
CONSENSUS:
$93.36
UPSIDE:
52.92%
Stock News
ADAR1 Capital Management LLC Acquires Shares of 166,286 Ionis Pharmaceuticals, Inc. $IONS
ADAR1 Capital Management LLC acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 166,286 shares of the company's stock, valued at approximately $13,185,000. ADAR1 Capital Management LLC owned
Breakfast News: A Conversation With Ionis CEO
Biotech has been hot in 2026. The sector, tracked by the SPDR S&P Biotech ETF, (XBI +1.44%) is up 39% year to date -- beating tech and running even with energy.
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA® (olezarsen), recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk o.
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?
Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report.
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. The acquisition increased the director's total direct and indirect equity holdings by 34%.
Insider Buying: Ionis Pharmaceuticals (NASDAQ:IONS) Director Buys $800,700.00 in Stock
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) Director Michael Hayden purchased 15,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, July 30th. The shares were acquired at an average cost of $53.38 per share, for a total transaction of $800,700.00. Following the transaction, the director directly owned 19,000 shares of the company's
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript
Ionis Pharmaceuticals Q2 Earnings Call Highlights
Ionis Pharmaceuticals NASDAQ: IONS reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch progress for TRYNGOLZA in severe hypertriglyceridemia.
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q2 Earnings: A Look at Key Metrics
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to earnings of $0.86 per share a year ago.
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027.“As a founding scientist, Frank has been instrumental in shaping Ionis and advancing the entire field of RNA-targeted medicines,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Frank's profound contributions include pioneering the use of antisense medicines in neurological.
Ionis reports second quarter 2026 financial results and highlights progress on key programs
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2026. “With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis to people living with severe hypertriglyceridemia. We are encouraged by the early launch momentum and look forward to accelerating growth from TRYNGOLZA and our ot.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Price Targets
Ionis Pharmaceuticals (IONS) PT Lowered to $115 at H.C. Wainwright
$115.00
(was $54.04)
Mitchell Kapoor
·
H.C. Wainwright
Ionis Pharmaceuticals price target raised to $69 from $66 at Goldman Sachs
$69.00
(was $54.04)
Goldman Sachs
Ionis Pharmaceuticals (IONS) PT Lowered to $89 at Guggenheim
$89.00
(was $52.95)
Debjit Chattopadhyay
·
Guggenheim
Ionis Pharmaceuticals price target lowered to $85 from $100 at RBC Capital
$85.00
(was $56.92)
Luca Issi
·
RBC Capital
Ionis Pharmaceuticals price target lowered to $110 from $130 at Morgan Stanley
$110.00
(was $59.89)
Morgan Stanley
Ionis Pharmaceuticals price target lowered to $95 from $110 at Canaccord
$95.00
(was $64.27)
Gary Nachman
·
Canaccord Genuity
Ionis Pharmaceuticals (IONS) PT Lowered to $90 at Barclays
$90.00
(was $64.27)
Eliana Merle
·
Barclays
Ionis Pharmaceuticals (IONS) PT Lowered to $90 at JefferiesMember Login
$90.00
(was $64.49)
Jefferies
Ionis Pharmaceuticals price target lowered to $86 from $105 at Needham
$86.00
(was $64.50)
Joseph Stringer
·
Needham
Ionis Pharmaceuticals price target lowered to $87 from $104 at Raymond James
$87.00
(was $64.29)
Raymond James
Ionis Pharmaceuticals price target raised to $130 from $125 at H.C. Wainwright
$130.00
(was $76.52)
H.C. Wainwright
Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs
$75.00
(was $76.52)
Goldman Sachs
Ionis Pharmaceuticals price target raised to $111 from $104 at Oppenheimer
$111.00
(was $75.43)
Oppenheimer
Ionis Pharmaceuticals price target raised to $125 from $120 at H.C. Wainwright
$125.00
(was $74.83)
H.C. Wainwright
Ionis Pharmaceuticals price target raised to $115 from $106 at Barclays
$115.00
(was $74.83)
Eliana Merle
·
Barclays
Ionis Pharmaceuticals price target raised to $130 from $95 at Morgan Stanley
$130.00
(was $74.07)
Morgan Stanley
Ionis Pharmaceuticals initiated with a Buy at Canaccord
$110.00
(was $74.87)
Canaccord Genuity
Ionis Pharmaceuticals resumed with an Outperform at Raymond James
$104.00
(was $75.41)
Tiago Fauth
·
Raymond James
Ionis Pharmaceuticals (IONS) PT Raised to $95 at Morgan Stanley
$95.00
(was $80.93)
Michael Ulz
·
Morgan Stanley
Ionis Pharmaceuticals price target raised to $103 from $90 at Needham
$103.00
(was $80.93)
Needham